Lung Cancer Therapeutics Market
Lung Cancer Therapeutics Market - Global Industry Assessment & Forecast
#
Pages:
210
2023
Sep - 2024
VMR-2568
Segments Covered
By
Therapy Radiation Therapy, Targeted Therapy, Immunotherapy, Chemotherapy, Others
-
By
Lung Cancer Type Small Cell Lung Cancer, Non-small Cell Lung Cancer, Lung Carcinoid Tumor
-
By
Distribution Channel Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
-
By
Type of Molecule Small molecules, Biologics
-
By
Drug Class Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors, Others
-
By
Region North America , Europe , Asia Pacific , Latin America , The Middle-East and Africa
Snapshot
 Base Year:
|
2023 |
| Forecast
Years:
|
2024 - 2032 |
 Historical
Years:
|
2018 - 2022 |
 Revenue
2023: |
USD 29.1 Billion |
 Revenue 2032:
|
USD 63.7 Billion |
 Revenue CAGR
(2024 - 2032): |
9.1 % |
Fastest Growing Region (2024 -
2032)
|
Asia Pacific |
Largest Region (2023):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
| Sr. No. | Offering | Report Coverage |
| 1. | Market Size | In terms of Revenue (USD Million) |
| 2. | Historic Data | 2018 to 2022 |
| 3. | Forecast Data | 2024 to 2032 |
| 4. | Market Drivers, Restraints, Opportunities, & Regional Market Trends | Yes |
| 5. | Market Attractiveness Analysis | Yes |
| 6. | Segment Analysis | Maximum Segments |
| 7. | Regional Coverage | 5 Regions |
| 8. | Country Coverage | Top 22 Countries |
| 9. | Competitive Landscape and Company Market Share Analysis | Yes. Exhaustive information will be provided in two separate chapters of Competitive Landscape and Company Profiles. |
| 10. | Porter’s Five Forces Analysis | Yes. |
| 11. | Value Chain Analysis | Yes |
| 12. | PEST Analysis | Yes |
| 13. | Regulatory Landscape | Yes |
| 14. | Technology Landscape | Yes |
| 15. | COVID-19 Impact Analysis | Yes. Exhaustive information for Key Strategies Undertaken by Companies, Impact Assessment of the COVID-19 Pandemic by Region, along with Short-term and Long-term dynamics. |
| 16. | Top startups to watch out for | Yes |
| 17. | Top 3 Trends to Watch | Yes |
| 18. | Top 3 Strategies Followed by Major Players | Yes |
| 19. | Top 3 Predictions by Vantage Market Research | Yes |
| 20. | Discussion Guide | Yes |
| 21. | Key Primary Respondents - VERBATIM | Yes |
| 22. | Transcripts from the Primary Respondents | Additional Cost USD 1,000 |
| 23. | Others/Miscellaneous | |
FAQ
Frequently Asked Question
What is the global demand for Lung Cancer Therapeutics in terms of revenue?
-
The global Lung Cancer Therapeutics valued at USD 29.1 Billion in 2023 and is expected to reach USD 63.7 Billion in 2032 growing at a CAGR of 9.1 %.
Which are the prominent players in the market?
-
The prominent players in the market are AstraZeneca PLC (UK), Boehringer Ingelheim International GmbH (Germany), Bristol Myers Squibb Company (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co. Inc. (U.S.), Pfizer Inc. (U.S.), Allergan Inc. (Ireland), Teva Pharmaceutical Industries Ltd. (Israel), Abbvie Inc. (U.S.), Johnson & Johnson (U.S.), Amgen Inc. (U.S.), Novartis AG (Switzerland).
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 9.1 % between 2024 and 2032.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Lung Cancer Therapeutics include
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Lung Cancer Therapeutics in 2023.
